Advances in membrane proteomics and cancer biomarker discovery: Current status and future perspective

Proteomics

Volumn 12, Issue 19-20, 2012, Pages 3085-3104

  Shukla, Hem D ^a   Vaitiekunas, Paulius ^a   Cotter, Robert J ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Biomedicine; Glycosylation; Membrane protein; Phosphorylation; Posttranslational modification

Indexed keywords

MEMBRANE PROTEIN; TUMOR MARKER;

CELL COMMUNICATION; GLYCOSYLATION; HUMAN GENOME; NITROSYLATION; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROCESSING; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; STOICHIOMETRY;

ANIMALS; GLYCOSYLATION; HUMANS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867753772     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201100519     Document Type: Review

References (178)

1. Blonder, J., Goshe, M. B., Moore, R. J., Pasa-Tolic, L. et al., Enrichment of integral membrane proteins for proteomic analysis using liquid chromatography-tandem mass spectrometry. J. Proteome Res. 2002, 1, 351-36.
2. Aebersold, R., Anderson, L., Caprioli, R., Druker, B. et al., Perspective: a program to improve protein biomarker discovery for cancer. J. Proteome Res. 2005, 4, 1104-1109.
3. Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C. et al., Initial sequencing and analysis of the human genome. Nature 2001, 409, 860-921.
4. Kohnke, P. L., Mulligan, S. P., Christopherson, R. I., Membrane proteomics for leukemia classification and drug target identification. Curr. Opin. Mol. Ther. 2009, 11, 603-610.
5. Dormeyer, W., van Hoof, D., Mummery, C. L., Krijgsveld, J. et al., A practical guide for the identification of membrane and plasma membrane proteins in human embryonic stem cells and human embryonal carcinoma cells. Proteomics 2008, 8, 4036-4053.
6. Foster, L. J., Zeemann, P. A., Li, C., Mann, M. et al., Differential expression profiling of membrane proteins by quantitative proteomics in a human mesenchymal stem cell line undergoing osteoblast differentiation. Stem Cells 2005, 23, 1367-1377.
7. Streuli, C. H., Integrins and cell-fate determination. J. Cell Sci. 2009, 122, 171-177.
8. Tan, F., Lu, L., Cai, Y., Wang, J. et al., Proteomic analysis of ubiquitinated proteins in normal hepatocyte cell line Chang liver cells. Proteomics 2008, 8, 2885-2896.
9. Dorsam, R. T., Gutkind, J. S., G-protein-coupled receptors and cancer. Nat. Rev. Cancer. 2007, 7, 79-94.
10. Patwardhan, A. M., Berg, K. A., Akopain, A. N., Jeske, N. A. et al., Bradykinin-induced functional competence and trafficking of the delta-opioid receptor in trigeminal nociceptors. J. Neurosci. 2005, 25, 8825-8832.
11. Cox, J., Mann, M., Is proteomics the new genomics? Cell 2007, 130, 395-398.
12. Zhang, Z., Zhang, L., Hua, Y., Jia, X. et al., Comparative proteomic analysis of plasma membrane proteins between human osteosarcoma and normal osteoblastic cell lines. BMC Cancer 2010, 10, 206-215.
13. Distler, A. M., Kerner, J., Hoppel, C. L., Proteomics of mitochondrial inner and outer membranes. Proteomics 2008, 8, 4066-4082.
14. Mann, M., Jensen, O. N., Proteomic analysis of post-translational modifications. Nat. Biotechnol. 2003, 21, 255-261.
15. Hanash, S., Taguchi, A., The grand challenge to decipher the cancer proteome. Nat. Rev. 2010, 10, 652-660.
16. Zhao, Y., Jensen, O. N., Modification-specific proteomics: strategies for characterization of post-translational modifications using enrichment techniques. Proteomics 2009, 9, 4632-4641.
17. Zhang, H., Guo, T., Li, X., Datta, A., Park, J. E. et al., Simultaneous characterization of glyco- and phosphoproteomes of mouse brain membrane proteome with electrostatic repulsion hydrophilic interaction chromatography. Mol. Cell. Proteomics 2010, 9, 635-647.
18. Weerapana, E., Imperiali, B., Asparagine-linked protein glycosylation: from eukaryotic to prokaryotic systems. Glycobiology 2006, 16, 91-101.
19. Peng, X.-Q., Wang, F., Geng, X., Zhang, W. F., Current advances in tumor proteomics and candidate biomarkers for hepatic cancer. Expert Rev. Proteomics 2009, 6, 551-561.
20. Wu, C. C., Yates, J. R., III, The application of mass spectrometry to membrane proteomics. Nat. Biotechnol. 2003, 21, 262-267.
21. Qiu, H., Wang, Y., Quantitative analysis of surface plasma membrane proteins of primary and metastatic melanoma cells. J. Proteome Res. 2008, 7, 1904-1915.
22. Kang, U. B., Ahn, Y., Lee, J. W., Kim, Y. H. et al., Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker. BMC Cancer 2010, 10, 114-123.
23. Tuli, R., Flynn, R. A., Brill, K. L., Sabol, J. L. et al., Diagnosis, treatment, and management of breast cancer in previously augmented women. Breast J. 2006, 12, 343-348.
24. Jemal, A., Bray F., Center M. M., Ferlay J. et al., Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
25. Hartwell, L., Mankoff, D., Paulovich, A., Ramsey, S. et al., Cancer biomarkers: a systems approach. Nat. Biotechnol. 2006, 24, 905-908.
26. Patwa, T. H., Wang, Y., Miller, F. R., Goodison, S. et al., A novel phosphoprotein analysis scheme for assessing changes in premalignant and malignant breast cell lines using 2-D liquid separations, protein microarrays, and tandem mass spectrometry. Proteomics Clin. Appl. 2009, 3, 51-66.
27. Wandall, H. H., Blixt, O., Tarp, M. A., Pedersen, J. W. et al., Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res. 2010, 70, 1306-1313.
28. Staubach, S., Razawi, H., Hanisch, F. G., Proteomics of MUC1-containing lipid rafts from plasma membranes and exosomes of human breast carcinoma cells MCF-7. Proteomics 2009, 9, 2820-2835.
29. Hattrup, C. L., Gendler, S. J., Structure and function of the cell surface (tethered) mucins. Annu. Rev. Physiol. 2008, 70, 431-457.
30. Jonckheere, N., Seuningen, I. V., The membrane-bound mucins: how large O-glycoproteins play key roles in epithelial cancers and hold promise as biological tools for gene-based and immunotherapies. Crit. Rev. Oncog. 2008, 14, 177-196.
31. James, C. R., Quinn, J. E., Mullan, P. B., Johnston, P. G. et al., BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist 2007, 12, 142-150.
32. Kennedy, R. D., Quinn, J. E., Mullan, P. B., Johnston, P. G. et al., The role of BRCA1 in the cellular response to chemotherapy. J. Nat. Cancer Inst. 2004, 96, 1659-1668.
33. Wang, X., Chao, L., Ma, G., Chen, L. et al., Increased expression of osteopontin in patients with triple-negative breast cancer. Eur. J. Clin. Invest. 2008, 38, 438-446.
34. Oldenhuis, C. N. A. M., Oostinga, S. F., Gietemaa, J. A., de Vries, E. G. E., Prognostic versus predictive value of biomarkers in oncology. Eur. J. Cancer 2008, 44, 946-953.
35. Molina, R., Augé, J. M., Escudero, J. M., Filella, X. et al., Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumor Biol. 2010, 31, 171-180.
36. Ji, H., Zangar, C., Protein modifications as potential biomarkers in breast cancer. Biomark. Insights 2009, 4, 191-200.
37. Carney, W. P., Circulating oncoprotein Her2/neu, EGFR, and CAIX as novel cancer biomarker. Expert Rev. Mol. Diagn. 2007, 7, 309-319.
38. Slamon, D. J, Clark, G. M., Wong S. G., Levin W. J. et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177-182.
39. Loo, L., Capobianco, J. A., Wu, W., Gao, X. et al., Highly sensitive detection of HER2 extracellular domain in the serum of breast cancer patients by piezoelectric microcantilevers. Anal Chem. 2011, 83, 3392-3397.
40. Lynch, H. T., Silva, E., Snyder, C., Lynch, J. F., Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes. Breast J. 2008, 14, 3-13.
41. Craven, R. J., PGRMC1: a new biomarker for estrogen-responsive breast cancers. Breast Cancer Res. 2008, 10, 113-114.
42. Rubinfeld, B., Upadhyay, A., Clark, S. L., Fong, S. E. et al., Identification and immunotherapeutic targeting of antigens induced by chemotherapy. Nat. Biotechnol. 2006, 24, 205-209.
43. Kuk C., Kulasingam, V., Gunawardana, C. G., Smith, C. R. et al., Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol. Cell. Proteomics 2009, 8, 661-669.
44. Gunawardana, C. G., Memari, N., Diamandis, E. P., Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays. Clin. Biochem. 2009, 42, 426-429.
45. Kulasingam, V., Pavlou, M. P., Diamandis, E. P., Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat. Rev. Cancer 2010, 10, 371-378.
46. Gortzak-Uzan, L., Ignatchenko, A., Evangelou, A. I., Agochiya, M. et al., A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J. Proteome Res. 2008, 7, 339-351.
47. Drapkin, R., von Horsten, H., Lin, Y., Mok, S. et al., Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005, 65, 2162-2169.
48. Huhtinen, K., Suvitie, P., Hiissa, J., Junnila J. et al., Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br. J. Cancer 2009, 100, 1315-1319.
49. Moore, R. G., Brown, A. K., Miller, M. C., Skates, S., et al., The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 2008, 108, 402-408.
50. Pitteri, S. J., JeBailey, L., Faça, V. M., Thorpe, J. D. et al., Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. Plos One 2009, 4, e7916.
51. Luborsky, J. L., Yu, Y., Edassery, S. L., Jaffar, J. et al., Autoantibodies to mesothelin in infertility. Cancer Epidemiol. Biomarkers Prev. 2011, 20, 1-9.
52. Hung, C. F., Calizo, R., Tsai, Y. C., He, L. et al., DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine 2007, 25, 127-135.
53. Hassan, R., Bera, B., Pastan, I., Mesothelin: a new target for immunotherapy. Clin. Cancer Res. 2004, 10, 3937-3942.
54. Hung, C.-F., Tsai, Y.-C., He, L., Wu, T.-C., Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther. 2007, 14, 921-929.
55. Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N. et al., Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006, 20, 1218-1249.
56. Jones, S., Zhang, X., Parsons, D. W., Lin, J. C. H. et al., Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321, 1801-1806.
57. Jones, S., Hruban, R. H., Kamiyama, M., Borges, M. et al., Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009, 324, 217-219.
58. Lacobuzio-Donahue, C. A., Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut 2011, 10, 1136.
59. Gronborg, M., Kristiansen, T. Z., Iwahori, A., Chang, R. et al., Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol. Cell. Proteomics 2006, 5, 157-171.
60. Real, F. X., Malats, N., Lesca, G., Porta, M. et al., Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancer. Gut 2002, 50, 653-657.
61. Tonack, S., Aspinall-O'Dea, M., Neoptolemos, J. P., Costello, E., Pancreatic cancer: proteomic approaches to a challenging disease. Pancreatology 2009, 9, 567-576.
62. Hanash, S. M., Pitteri, S. J., Faca, V. M., Mining the plasma proteome for cancer biomarkers. Nature 2008, 452, 571-579.
63. Pan, S., Chen, R., Reimel, B. A., Crispin, D. A. et al., Quantitative proteomics investigation of pancreatic intraepithelial neoplasia. Electrophoresis 2009, 30, 1132-1144.
64. Shen, J., Person, M. D., Zhu, J., Abbruzzese, J. L. et al., Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 2004, 64, 9018-9026.
65. Hoshi, H., Sawada, T., Uchida, M., Saito, H. et al., Tumor-associated MUC5AC stimulates in vivo tumorigenicity of human pancreatic cancer. Int. J. Oncol. 2011, 38, 619-627.
66. Sheehan, J. K., Brazeau, C., Kutay, S., Pigeon, H. et al., Physical characterization of the MUC5AC mucin: a highly oligomeric glycoprotein whether isolated from cell culture or in vivo from respiratory mucous secretions. Biochem. J. 2000, 347, 37-44.
67. Ho, J. J. L., Mucins in the diagnosis and therapy of pancreatic cancer. Curr. Pharm. Des. 2000, 6, 1881-1896.
68. Goggins, M., Markers of pancreatic cancer: working toward early detection. Clin. Cancer Res. 2011, 17, 635-637.
69. Brand, R. E., Nolen, B. M., Zeh, H. J., Allen, P. J. et al., Serum biomarker panels for the detection of pancreatic cancer. Clin. Cancer Res. 2011, 17, 805-816.
70. Pan, P., Chen, R., Crispin, D. A., May, D. et al., Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling. J. Proteome Res. 2011, 10, 2359-2376.
71. Ottenhof, N. A., deWilde, R. F., Maitra, A., Hruban, R.H. et al., Molecular characteristics of pancreatic ductal adenocarcinoma. Pathol. Res. Int. 2011, 2011, 2011:620601.
72. Sawai, H., Takeyama, H., Yamamoto, M., Furuta, A., et al., Enhancement of integrins by interleukin-1α, and their relationship with metastatic and invasive behavior of human pancreatic ductal adenocarcinoma cells. J. Surg. Oncol. 2003, 82, 51-56.
73. Volonte, D., Galbiati, F., Pestell, R. G., Lisanti, M. P., Cellular stress induces the tyrosine phosphorylation of caveolin-1 (Tyr14) via activation of p38 mitogen-activated protein kinase and c-Src kinase. Evidence for caveolae, the actin cytoskeleton, and focal adhesions as mechanical sensors of osmotic stress. J. Biol Chem. 2001, 16, 8094-8103.
74. Desgrosellier, J. S., Cheresh, D. A., Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10, 9-22.
75. Shukla, H. D., Vaitiekunas, P., Proteomic analysis of integrin signaling pathway in pancreatic carcinoma cell lines (BxPC-3) and targets for therapeutic intervention. 7th EDRN Workshop, NCI 2011, P6.
76. McLean, G. W., Carragher, N. O., Avizienyte, E., Evans, J. et al., The role of focal-adhesion kinase in cancer a new therapeutic opportunity. Nat. Rev. Cancer 2005, 5, 505-515.
77. Niu, W., Liu, X., Zhang, Z., Xu, K. et al., Effects of αvβ6 gene silencing by RNA interference in PANC-1 pancreatic carcinoma cells. Anticancer Res. 2010, 30, 135-142.
78. Egler, R. A., Fernandes, E., Rothermund, K., Sereika, S. et al. Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1. Oncogene 2005, 24, 8038-8050.
79. Sullivan, R., Graham, C. H. Chemosensitization of cancer by nitric oxide. Curr. Pharm. Des. 2008, 14, 1113-1123.
80. Chen, E. I., Hewel, J., Krueger, J. S., Tiraby, C. et al., Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res. 2007, 67, 1472-1486.
81. Trachootham, D., Alexandre, J., Huang, P., Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 2009, 8, 579-591.
82. Ferlay, J., Shin, H. R., Bray, F., Forman, D. et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893-2917.
83. Cooperberg, M. R., Moul, J. W., Carroll, P. R., The changing face of prostate cancer. J. Clin. Oncol. 2005, 23, 8146-8151.
84. Frydenberg, M., Stricker, P. D., Kaye, K. W., Prostate cancer diagnosis and management. Lancet 1997, 349, 1681-1687.
85. Shah, R. B., Mehra, R., Chinnaiyan, A. M., Shen, R. et al., Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004, 64, 9209-9216.
86. Kumar, A., Mikolajczyk, S. D., Goel, A. S., Millar, L. S. et al., Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. 1997, 57, 3111-3114.
87. Tajiri, M., Ohyama, C., Wada, Y., Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach. Glycobiology 2008, 18, 2-8.
88. Sardana, G., Dowell, B., Diamandis, E. P., Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin. Chem. 2008, 54, 1951-1960.
89. Kulasingam, V., Diamandis, E. P., Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 2008, 5, 588-599.
90. Raaijmakers, R., Wildhagen, M. F., Ito, K., Pàez, A. et al., Prostate-specific antigen change in the European randomized study of screening for prostate cancer, section Rotterdam. Urology 2004, 63, 316-320.
91. Varambally, S., Laxman, B., Mehra, R., Cao, Q. et al., Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia 2008, 10, 1285-1294.
92. Troyer, J. K., Beckett, M. L., Wright, G. L., Jr., Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer 1995, 62, 552-558.
93. Bouchelouche, K., Choyke, P. L., Capala, J., Prostate specific membrane antigen-a target for imaging and therapy with radionuclides. Discov. Med. 2010, 9, 55-61.
94. Wright, G. L., Haley, C., Beckett, M. L., Schelhammer, P. F., Expression of prostate-specific membrane antigen in normal, benign and malignant prostate tissues. Urol. Oncol. 1995, 1, 18-28.
95. Castelletti, D., Fracasso, G., Alfalah, M., Cingarlini, S. et al., Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing. JBC 2006, 281, 3505-3512.
96. Parkin, D. M., Bray, F., Ferlay, J., Pisani, P., Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55, 74-108.
97. Spira, A., Beane, J., Shah, V., Liu, G. et al., Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc. Natl. Acad. Sci. USA 2004, 101, 10143-10148.
98. Jemal, A., Siegel, R., Ward, E., Hao, Y. et al., Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58, 71-96.
99. Chapman, C. J., Murray, A., McElveen, J.E., Sahin, U. et al., Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 2008, 63, 228-233.
100. Chapman, C. J., Thorpe, A. J., Murray, A., Parsy-Kowalska, C. B. et al., Immunobiomarkers in small cell lung cancer: potential early cancer signals. Clin. Cancer Res. 2011, 17, 1474-1480.
101. Ostroff, R. M., Bigbee, W. L., Franklin, W., Gold, L. et al., Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS ONE 2010, 5, e15003.
102. Gogali, A., Charalabopoulos, K., Zampira, I., Konstantinidis, A. K. et al., Soluble adhesion molecules E-cadherin, ICAM-1 and E-selectin as lung cancer biomarkers. Chest 2010, 138, 1173-1179.
103. Planque, C, Kulasingam, V., Smith, C. R., Reckamp, K. et al., Identification of five candidate lung cancer biomarkers by proteomic analysis of conditioned media of four lung cancer cell lines. Mol. Cell. Proteomics 2009, 8, 2746-2758.
104. Duffy, M. J., Mullooly, M., O'Donovan, N., Sukor, S. et al., The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clin. Proteomics 2011, 8, 9-22.
105. Zhou, B. B., Peyton, M., He, B., Liu, C. et al., Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006, 10, 39-50.
106. Lau, K. S., Dennis, J. W., N-glycans in cancer progression. Glycobiology 2008, 18, 750-760.
107. Yu, Y., Hao, Y., Feig, L. A., The R-Ras GTPase mediates cross talk between estrogen and insulin signaling in breast cancer cells. Mol. Cell. Biol. 2006, 26, 6372-6380.
108. Roberts, P. J., Der, C. J., Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26, 3291-3310.
109. Spickett, C. M., Pitt, A. R., Morrice, N., Kolch, W., Proteomic analysis of phosphorylation, oxidation and nitrosylation in signal transduction. Biochim. Biophys. Acta 2006, 1764, 1823-1841.
110. Cohen, P., The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture. Eur. J. Biochem. 2001, 268, 5001-5010.
111. Perkins, N. D., Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 2006, 25, 6717-6730.
112. Brooks, S. A., Carter, T. M., Royle, L., Harvey, D. J. et al., Altered glycosylation of proteins in cancer: what is the potential for new anti-tumour strategies. Anticancer Agents Med. Chem. 2008, 8, 2-21.
113. Kobata, A., Amano, J., Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol. Cell Biol. 2005, 83, 429-439.
114. Krueger, K. E., Srivastava, S., Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. Mol. Cell. Proteomics 2006, 5, 1799-1810.
115. Misek, D. E., Kim, E. H., Protein biomarkers for the early detection of breast cancer. Int. J. Proteomics 2011, 343582xs.
116. Whelan, S. A., Lu, M., He, J., Yan, W. et al., Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers. J. Proteome Res. 2009, 8, 4151-4160.
117. Jankovic, M., Milutinovic, B. S., Glycoforms of CA125 antigen as a possible cancer marker. Cancer Biomark. 2008, 4, 35-42.
118. Kuzmanov, U., Jiang, N., Smith, C. R., Soosaipillai, A. et al., Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system. Mol. Cell. Proteomics 2009, 8, 791-798.
119. Singh, A. P., Chaturvedi, P., Batra, S. K., Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res. 2007, 67, 433-436.
120. Contessa, J. N., Bhojani, M. S., Freeze, H. H., Rehemtulla, A. Z. et al., Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res. 2008, 68, 3803-3809.
121. Wang, Y., Ao, X., Vuong, H., Konanur, M. et al., Membrane glycoproteins associated with breast tumor cell progression identified by a lectin affinity approach. J. Proteome Res. 2008, 7, 4313-4325.
122. Iacobelli, S., Arno, E., D'Orazio, A. Coletti, G. et al., Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res. 1986, 46, 3005-3010.
123. Yi, J. K., Chang, J. W., Han, W., Lee, J. W. et al., Autoantibody to tumor antigen, alpha 2-HS glycoprotein: a novel biomarker of breast cancer screening and diagnosis. Cancer Epidem. Biomar. 2009, 18, 1357-1364.
124. Contessa, J. N., Bhojani, M. S., Freeze, H. H., Rehemtulla, A. et al., Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res. 2008, 68, 3803-3809.
125. Wang, Y., Ao, X., Vuong, H., Konanur, M. et al., Membrane glycoproteins associated with breast tumor cell progression identified by a lectin affinity approach. J. Proteome Res. 2008, 7, 4313-4325.
126. Peracaula, R., Royle, L., Tabares, G., Mallorqui-Fernández, G. et al., Glycosylation of human pancreatic ribonuclease: differences between normal and tumor states. Glycobiology 2003, 13, 227-244.
127. Liu, Y. C., Yena, H. Y., Chena, C.-Y., Chenb, C.-H. et al., Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc. Natl. Acad. Sci. USA 2011, 108, 11332-11337.
128. Meany, D. L., Chan, D. W., Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin. Proteomics 2011, 8, 7-21.
129. Wong, C. H., Protein glycosylation: New challenges and opportunities. J. Org. Chem. 2005, 70, 4219-4225.
130. Abd Hamid, U. M., Royle, L., Saldova, R., Radcliffe, C. M. et al., A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology 2008, 18, 1105-1118.
131. Arnold, J. N., Saldova, R., Abd Hamid, U. M., Rudd, P. M., Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 2007, 8, 3284-3293.
132. Packer, N. H., von der Lieth, C. W., Aoki-Kinoshita, K. F., Lebrilla, C. B. et al., Frontiers in glycomics: bioinformatics and biomarkers in disease. Proteomics 2008, 8, 8-20.
133. Taniguchi, N., Human disease glycomics/proteome initiative (HGPI). Mol. Cell. Proteomics 2008, 7, 626-627.
134. Hakomori, S., Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl. Acad. Sci. USA 2002, 99, 10231-10233.
135. Nita-Lazar, M., Noonan, V., Rebustini, I., Walker, J. et al. Overexpression of DPAGT1 leads to aberrant N-glycosylation of E-cadherin and cellular discohesion in oral cancer. Cancer Res. 2009, 69, 5673-5680.
136. Taylor, A. D., Hancock, W. S., Hincapie, M., Taniguchi, N. et al., Towards an integrated proteomic and glycomic approach to finding cancer biomarkers. Genome Med. 2009, 1, 57-67.
137. Varki, A., Cummings, R. D., Esko, J. D., Freeze, H. H. et al., Essentials of Glycobiology, 2nd edn., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 2009.
138. Kaji, H., Saito, H., Yamauchi, Y., Shinkawa, T., Lectin affinity capture, isotope-coded tagging and mass spectrometry to identify N-linked glycoproteins. Nat. Biotechnol. 2003, 6, 667-672.
139. Kaji, H., Yamauchi, Y., Takahashi, N., Isobe, T., Mass spectrometric identification of N-linked glycopeptides using lectin-mediated affinity captureand glycosylation site-specific stable isotope tagging. Nat. Protocols 2006, 1, 3019-3027.
140. Wada, Y., Tajiri, M., Yoshida, S., Hydrophilic affinity isolation and MALDI multiple-stage tandem mass spectrometry of glycopeptides for glycoproteomics. Anal. Chem. 2004, 76, 6560-6565.
141. Wang, M., Long, R. E., Comunale, M. A., Junaidi, O., Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 1914-1921.
142. Narimatsu, H., Sawaki, H., Kuno, A., Kaji, H., A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics. FEBS J. 2010, 277, 95-105.
143. Kuno, A., Uchiyama, N., Koseki-Kuno, S., Ebe Y., Evanescent-field fluorescence-assisted lectin microarray: a new strategy for glycan profiling. Nat. Methods 2005, 2, 851-856.
144. Pilobello, K. T., Krishnamoorthy, L., Slawek, D., Mahal, L. K., Development of a lectin microarray for the rapid analysis of protein glycopatterns. Chembiochem. 2005, 6, 985-999.
145. Uchiyama, N., Kuno, A., Tateno, H., Kubo, Y. et al., Optimization of evanescent-field fluorescence-assisted lectin microarray for high sensitivity detection of monovalent oligosaccharides and glycoproteins. Proteomics 2008, 8, 3042-3050.
146. Tateno, H., Uchiyama, N., Kuno, A., Togayachi, A. et al., A novel strategy for mammalian cell surface glycome profiling using lectin microarray. Glycobiology 2007, 17, 1138-1146.
147. Zhu, J., He, J., Liu, Y, Simeone, D. M. et al., Identification of glycoprotein markers for pancreatic cancer CD24+CD44+ stem-like cells using nano-LC-MS/MS and tissue microarray. J. Proteome Res. 2012, 11, 2272-2281.
148. Fry, S. A., Afrough, B., Lomax-Browne, H. J., Timms, J. F., Lectin microarray profiling of metastatic breast cancers. Glycobiology 2011, 21, 1060-1070.
149. Qiu, Y. H., Patwa, T. H., Xu, L., Shedden, K. et al., Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J. Proteome Res. 2008, 7, 1693-1703.
150. Fuster, M. M., Esko, J. D., The sweet and sour of cancer: glycans as novel therapeutic target. Nat. Rev. Cancer 2005, 5, 526-542.
151. Dube, D. H., Bertozzi, C. R., Glycans in cancer and inflammation: potential for therapeutics and diagnostics. Nat. Rev. Drug Disc. 2005, 4, 477-488.
152. Drake, P. M., Cho, W., Li, W., Prakobphol, A. et al., Sweetening the pot: adding glycosylation to the biomarker discovery equation. Clin. Chem. 2010, 56, 223-236.
153. Miyagi1, T., Wada, T., Yamaguchi, K., Shiozaki1, K. et al., Human sialidase as a cancer marker. Proteomics 2008, 8, 3303-3311.
154. Varki, N. M., Varki, A., Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab. Invest. 2007, 87, 851-857.
155. Pérez-Garay, M., Arteta, B., Pagès, L., de Llorens, R. et al., α2, 3-sialyltransferase ST3Gal III modulates pancreatic cancer cell motility and adhesion in vitro and enhances its metastatic potential in vivo. PLoS ONE 2010, 5, e12524.
156. Liu, Y.-C., Yung-Yena, H.-Y., Chen, C.-Y., Chen, C.-H. et al., Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc. Natl. Acad. Sci. USA 2011, 108, 11332-11337.
157. Yang, L., Nyalwidhe, J. N., Guo, S., Drake, R. R. et al., Targeted identification of metastasisassociated cell-surface sialoglycoproteins in prostate cancer. Mol. Cell. Proteomics 2011, 10, 1-16.
158. Babal, P., Janega, P., Cerna, A., Kholova, I. et al., Neoplastic transformation of the thyroid gland is accompanied by changes in cellular sialylation. Acta Histochem. 2006, 108, 133-140.
159. Tian, Y., Esteva, F. J., Song, J., Zhang, H., Altered expression of sialylated glycoproteins in breast cancer using hydrazide chemistry and mass spectrometry. Mol. Cell. Proteomics 2012, 11, M111.011403.
160. Almaraz, R. T., Tian, Y., Bhattarcharya, R., Tan, E., Metabolic flux increases glycoprotein sialylation: implications for cell adhesion and cancer metastasis. Mol. Cell. Proteomics 2012, 11, M112.017558.
161. Wang, H., Wong, C.-H., Chin, A., Taguchi, A. et al., Integrated mass spectrometry-based analysis of plasma glycoproteins and their glycan modifications. Nat. Protocols 2011, 6, 253-259.
162. Mayya, V., Lundgren, D. H., Hwang, S., II, Rezaul, K. et al., Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci. Signal. 2009, 2, ra46.
163. Pal, M., Moffa, A., Sreekumar, A., Ethier, S. et al., Differential phosphoprotein mapping in cancer cells using protein microarrays produced from 2-D liquid fractionation. Anal. Chem. 2006, 78, 702-710.
164. Wolf-Yadlin, A., Kumar, N., Zhang, Y., Hautaniemi, S. et al., Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol. Syst. Biol. 2006, 2, 54-69.
165. Zarling, A. L., Polefrone, J. M., Evans, A. M., Mikesh L. M. et al., Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc. Natl. Acad. Sci. USA 2006, 103, 14889-14894.
166. Easty, D. J., Bennett, D. C., Protein tyrosine kinases in malignant melanoma. Melanoma Res. 2000 10, 401-411.
167. Cicenas, J., Urban, P., Kung, W., Vuaroqueaux, V. et al., Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur. J. Cancer 2006, 42, 636-645.
168. Frogne, T., Laenkholm, A. V., Lyng, M. B., Henriksen, L. K. et al., Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res. 2009, 11, R44-R69.
169. Lemjabbar-Alaoui, H., Sidhu, S. S., Mengistab, A., Gallup, M. et al., TACE/ADAM-17 phosphorylation by PKC-epsilon mediates premalignant changes in tobacco smoke-exposed lung cells. PLoS ONE 2011, 6, e17489.
170. Fischer, O. M., Gschwind, A., Ullrich, A. A., Cell surface growth factor receptor molecules as targets for cancer therapy. Discov. Med. 2004, 22, 166-171.
171. Fedorov, O., Muller, S., Knapp, S., The (un)targeted cancer kinome. Nat. Chem. Biol. 2010, 6, 166-169.
172. Rubbi, L., Titz, B., Brown, L., Galvan, E. et al., Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling. Sci. Signal 2011, 4, ra18.
173. Bodenmiller, B., Mueller, L. N., Mueller, M., Domon, B. et al., Reproducible isolation of distinct, overlapping segments of the phosphoproteome. Nat. Meth. 2007, 4, 231-237.
174. Larsen, M. R., Thingholm, T. E., Jensen, O. N., Roepstorff, P. et al., Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol. Cell. Proteomics 2005, 4, 873-886.
175. Rush, J., Moritz, A., Lee, K. A., Guo, A. et al., Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat. Biotechnol. 2004, 23, 94-101.
176. Chen, L., Fang, B., Giorgianni, F., Gingrich, J. R. et al., Investigation of phosphoprotein signatures of archived prostate cancer tissue specimens via proteomic analysis. Electrophoresis 2011, 32, 1984-1991.
177. Takano, S., Sogawa, K., Yoshitomi, H., Shida, T. et al., Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer. Br. J. Cancer 2010, 103, 223-231.
178. Froesch, M., Bindila, L. M., Baykut, G., Allen, M. et al., Coupling of fully automated chip electrospray to Fourier transform ion cyclotron resonance mass spectrometry for high- performance glycoscreening and sequencing. Rapid Commun. Mass Spectrom. 2004, 18, 3084-3092.